Compare Illumina, Inc. (ILMN) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Iron Mountain Inc — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while Iron Mountain Inc trades at $122.75 (market cap $36.19B). The key difference: Iron Mountain Inc is the larger of the two by market cap, and Iron Mountain Inc pays a 2.84% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | IRM | |
|---|---|---|
Market Cap | $28.96B | $36.19B |
Sector | Health | Real Estate |
52-Week High | $205.10 | $133.06 |
52-Week Low | $91.00 | $78.86 |
Enterprise Value | $30.32B | $55.60B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Iron Mountain (IRM) trades at $121.15, down 0.66% on the day, amid a bearish technical signal. The company reported strong Q2 2026 results with revenue up 19% year-over-year to $2.03 billion, beating estimates, and has a consensus analyst price target of $141.50. However, high debt levels and a negative shareholder equity position present fundamental concerns.
Outlook is mixed: robust data center and digital growth support upside, but elevated valuation ratios and rising debt-to-asset ratios pose risks. Analyst sentiment is predominantly buy-rated (65%), yet technical indicators suggest near-term caution. Investors should weigh strong operational performance against financial leverage and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
